65,437 trials
Erectile Dysfunction
Primary: Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse — 14.1; 27.8; 43.4…
Myocardial Perfusion Imaging · Magnetic Resonance Imaging
Primary: Percentage Agreement Between Gadobutrol Perfusion Magnetic Resonance Imaging (MRI) (Blinded Reading) and SPECT (Central Reading) Regarding the Diagnosis for Detection of…
Carcinoma · Non-small Cell Lung Cancer
Primary: Metabolic Response Conversion Rate Between 3 and 6 Weeks After Starting Chemotherapy at a Threshold of a 20% Decrease in SUVmean — 10 Participants
Smokers
Primary: Percent Compliance With Chantix — 90.7; 85.8; 87.1; 91.7 Percentage of Participants
Japanese Encephalitis
Primary: Seroconversion Rate — 98.5 percent
Infections, Papillomavirus
Primary: Geometric Mean Titers (GMTs) for Antibodies Against Human Papillomavirus (HPV)-16/18 Antigens — 18347.1; 5.0; 7960.2; 4.1 EL.U/mL
Major Depressive Disorder
Primary: Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185 — 30.2; 14.3 percent estimated…
Major Depressive Disorder
Primary: Change From Randomization in Montgomery and Asberg Depression Rating Scale (MADRS) — -12.5; -12.3 units on a scale
Obesity
Primary: Change in BMI (Body Mass Index) — -0.74; 1.33; -0.18; 0.98 kg/m^2 — p=0.03
Asthma
Primary: Forced Expiratory Volume (FEV1) Peak (0-3h) Response — 0.489; 0.556; 0.546; 0.602 Litre — p=0.0043
Venous Thromboembolism
Primary: Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related…
Typhoid Fever
Primary: Number of Infants With Adverse Reactions After Vaccination — 22; 24; 17; 7 participants
Alzheimer's Disease
Primary: Inter-reader Agreement - Median Kappa Statistic — 0.72; 0.70; 0.25; 0.75 median kappa
Non-Hodgkin's Lymphoma
Primary: Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2 — 1.1…
Multiple Sclerosis
Primary: Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24 — 0.203; 0.208; 0.403 relapses per year